Company intelligence / Profile preview

Australis Pharma

Simi Valley, California, United Statesaustralispharma.com ↗

Ownership: Private
Development stage: Other

Overview

Australis Pharma has developed a proprietary chemical library from a natural source and validated several compounds in preclinical studies. Their lead compound AUS_001 shows broad anti-cancer efficacy with low side effects and oral administration potential. The company focuses on overcoming drug resistance and improving patient experience in oncology. All pipeline assets remain at the preclinical stage; no clinical results have been reported yet.

Therapeutic areas: GastroenterologyNeurologyOncology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Drug pipeline

1 asset

AUS_001

Preclinical

Beyond the preview

Go deeper on Australis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Australis Pharma.

Explore the full profile